Literature DB >> 18781885

Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status.

Richard D Moore1, Kelly A Gebo, Gregory M Lucas, Jeanne C Keruly.   

Abstract

The rate of comorbidities not related to human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) among HIV-infected patients may be higher than expected. We assessed the incidence of comorbidities not related to HIV infection or AIDS by CD4 cell count and highly active antiretroviral therapy (HAART) use status in an HIV clinical practice. A total of 2824 patients contributed 9172 person-years of longitudinal data during the period 1997-2006. Among patients with a CD4 cell count <350 cells/mm(3), receipt of HAART was associated with a significantly decreased incidence of comorbidities not related to HIV infection or AIDS.

Entities:  

Mesh:

Year:  2008        PMID: 18781885      PMCID: PMC2597666          DOI: 10.1086/592115

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

Review 1.  U.S. disparities in health: descriptions, causes, and mechanisms.

Authors:  Nancy E Adler; David H Rehkopf
Journal:  Annu Rev Public Health       Date:  2008       Impact factor: 21.981

2.  Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort.

Authors:  R D Moore
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

3.  Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Authors:  Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

4.  Estimating the proportion of patients infected with HIV who will die of comorbid diseases.

Authors:  R Scott Braithwaite; Amy C Justice; Chung-Chou H Chang; Jennifer S Fusco; Stephen R Raffanti; John B Wong; Mark S Roberts
Journal:  Am J Med       Date:  2005-08       Impact factor: 4.965

5.  Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states.

Authors:  Kelly A Gebo; John A Fleishman; Richard D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2005-12-15       Impact factor: 3.731

6.  Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol.

Authors:  Dominique Salmon-Ceron; Charlotte Lewden; Philippe Morlat; Sibylle Bévilacqua; Eric Jougla; Fabrice Bonnet; Laurence Héripret; Dominique Costagliola; Thierry May; Geneviève Chêne
Journal:  J Hepatol       Date:  2005-06       Impact factor: 25.083

7.  Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.

Authors:  Fabrice Bonnet; Charlotte Lewden; Thierry May; Laurence Heripret; Eric Jougla; Sibylle Bevilacqua; Dominique Costagliola; Dominique Salmon; Geneviève Chêne; Philippe Morlat
Journal:  Cancer       Date:  2004-07-15       Impact factor: 6.860

8.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

Review 9.  Racial and ethnic disparities in the VA health care system: a systematic review.

Authors:  Somnath Saha; Michele Freeman; Joahd Toure; Kimberly M Tippens; Christine Weeks; Said Ibrahim
Journal:  J Gen Intern Med       Date:  2008-02-27       Impact factor: 5.128

10.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

  10 in total
  22 in total

1.  Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis.

Authors:  Pragna Patel; Charles E Rose; Pamela Y Collins; Bernardo Nuche-Berenguer; Vikrant V Sahasrabuddhe; Emmanuel Peprah; Susan Vorkoper; Sonak D Pastakia; Dianne Rausch; Naomi S Levitt
Journal:  AIDS       Date:  2018-07-01       Impact factor: 4.177

Review 2.  Antiretroviral therapy: Shifting sands.

Authors:  V K Sashindran; Rajeev Chauhan
Journal:  Med J Armed Forces India       Date:  2016-01-05

3.  Psychosocial factors as predictors of HIV/AIDS risky behaviors among people living with HIV/AIDS.

Authors:  Gemechu B Gerbi; Tsegaye Habtemariam; Vinaida Robnett; David Nganwa; Berhanu Tameru
Journal:  J AIDS HIV Res       Date:  2012-01-01

4.  Experienced discrimination and racial differences in leukocyte gene expression.

Authors:  April D Thames; Michael R Irwin; Elizabeth C Breen; Steve W Cole
Journal:  Psychoneuroendocrinology       Date:  2019-04-19       Impact factor: 4.905

5.  Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population.

Authors:  Daniel R Drozd; Mari M Kitahata; Keri N Althoff; Jinbing Zhang; Stephen J Gange; Sonia Napravnik; Greer A Burkholder; William C Mathews; Michael J Silverberg; Timothy R Sterling; Susan R Heckbert; Matthew J Budoff; Stephen Van Rompaey; Joseph A C Delaney; Cherise Wong; Weiqun Tong; Frank J Palella; Richard A Elion; Jeffrey N Martin; John T Brooks; Lisa P Jacobson; Joseph J Eron; Amy C Justice; Matthew S Freiberg; Daniel B Klein; Wendy S Post; Michael S Saag; Richard D Moore; Heidi M Crane
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

6.  Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use?

Authors:  Nancy F Crum-Cianflone; Greg Grandits; Sara Echols; Anuradha Ganesan; Michael Landrum; Amy Weintrob; Robert Barthel; Brian Agan
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

7.  Haemoglobin and anaemia in the SMART study.

Authors:  Amanda Mocroft; Alan R Lifson; Giota Touloumi; Jacqueline Neuhaus; Zoe Fox; Adrian Palfreeman; Michael J Vjecha; Sally Hodder; Stephane De Wit; Jens D Lundgren; Andrew N Phillips
Journal:  Antivir Ther       Date:  2011

8.  CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy.

Authors:  Jessica L Castilho; Bryan E Shepherd; John Koethe; Megan Turner; Sally Bebawy; James Logan; William B Rogers; Stephen Raffanti; Timothy R Sterling
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177

9.  Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.

Authors:  Nikolas Wada; Lisa P Jacobson; Mardge Cohen; Audrey French; John Phair; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2013-01-03       Impact factor: 4.897

Review 10.  Patient-centered care for people living with multimorbidity.

Authors:  Cynthia M Boyd; Gregory M Lucas
Journal:  Curr Opin HIV AIDS       Date:  2014-07       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.